Predictive Role of Molecular Subtypes in Response to Neoadjuvant Chemotherapy in Breast Cancer Patients in Northeast China |
Lv, Minhao
(Department of Surgical Oncology, Department of Breast Surgery, The First Affiliated Hospital of China Medical University)
Li, Beibei (Department of Obstetrics and Gynecology, The Affiliated Shengjing Hospital of China Medical University) Li, Yongfeng (Department of Surgical Oncology, Department of Breast Surgery, The First Affiliated Hospital of China Medical University) Mao, Xiaoyun (Department of Surgical Oncology, Department of Breast Surgery, The First Affiliated Hospital of China Medical University) Yao, Fan (Department of Surgical Oncology, Department of Breast Surgery, The First Affiliated Hospital of China Medical University) Jin, Feng (Department of Surgical Oncology, Department of Breast Surgery, The First Affiliated Hospital of China Medical University) |
1 | Fisher B, Brown A, Mamounas E, et al (1997). Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 15, 2483-93. DOI |
2 | Mieog JS, van der Hage JA, van de Velde CJ (2007). Neoadjuvant chemotherapy for operable breast cancer. Br J Surg, 94, 1189-200. DOI ScienceOn |
3 | Rastogi P, Anderson SJ, Bear HD, et al (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85. DOI ScienceOn |
4 | Van Der Hage JA, van de Velde CJ, Julien JP, et al (2001). Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol, 19, 4224-37. DOI |
5 | Kim SI, Sohn J, Koo JS, et al (2010). Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology, 79, 324-30. DOI ScienceOn |
6 | Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. DOI ScienceOn |
7 | Hugh J, Hanson J, Cheang MC, et al (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical defi nition in the BCIRG 001 trial. J Clin Oncol, 27, 1168-76. DOI ScienceOn |
8 | Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74. DOI ScienceOn |
9 | Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defi ned by fi ve biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76. DOI ScienceOn |
10 | Livasy CA, Karaca G, Nanda R, et al (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 19, 264-71. DOI ScienceOn |
11 | Carey LA, Dees EC, Sawyer L, et al (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 13, 2329-34. DOI ScienceOn |
12 | James K, Eisenhauer E, Christian M, et al (1999). Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst, 91, 523-8. DOI ScienceOn |
13 | Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52. DOI ScienceOn |
14 | Peppercorn J, Perou CM, Carey LA (2008). Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest, 26, 1-10. DOI ScienceOn |
15 | De Ronde JJ, Hannemann J, Halfwerk H, et al (2010). Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat, 119, 119-26. DOI ScienceOn |
16 | Huober J, von Minckwitz G, Denkert C, et al (2010). Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat, 124, 133-40. DOI ScienceOn |
17 | Bhargava R, Beriwal S, Dabbs DJ, et al (2010). Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy : A single institutional experience with 359 cases. Cancer, 116, 1431-9. DOI ScienceOn |
18 | Rastogi P, Anderson SJ, Bear HD, et al (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85. DOI ScienceOn |
19 | Straver ME, Rutgers EJ, Rodenhuis S, et al (2000).The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol, 17, 2411-8. |
20 | Fisher B, Bryant J, Wolmark N, et al (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 16, 2672-85. DOI |
21 | Carey LA, Metzger R, Dees EC, et al (2005). American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst, 97, 1137-42. DOI ScienceOn |
22 | Parker JS, Mullins M, Cheang MC, et al (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol, 27, 1160-7. DOI ScienceOn |
23 | Blows FM, Driver KE, Schmidt MK, et al (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 7, e1000279. DOI ScienceOn |
24 | Rodenhuis S, Mandjes IA, Wesseling J, et al (2010). A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol, 21, 481-7. DOI ScienceOn |
25 | Kim R, Osaki A, Toge T (2005). Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Breast Cancer, 6, 223-32. DOI ScienceOn |
26 | Peintinger F, Symmans WF, Gonzalez-Angulo AM, et al (2006). The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 107, 1248-54. DOI ScienceOn |
27 | Thomas A, Ohlinger R, Hauschild M, et al (2006). Options and limits of surgery after pre-operative chemotherapy in breast cancer. Anticancer Res, 26, 1677-82. |
28 | Chang HR , Glaspy J , Allison MA, et al (2010). Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer, 116, 4227-37. DOI ScienceOn |
29 | Gogas H, Pectasides D, Kostopoulos I, et al (2010). Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II trial of the Hellenic Cooperative Oncology Group. Clin Breast Cancer, 10, 230-7. DOI ScienceOn |
30 | Staudacher L, Cottu PH, Diéras V, et al (2011). Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol, 22, 848-56. DOI ScienceOn |
31 | Goldstein NS, Decker D, Severson D, et al (2007). Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 110, 1687-96. DOI ScienceOn |
32 | Andre F, Mazouni C, Liedtke C, et al (2008). HER2 expression and efficacy of preoperative paclitaxel/ FAC chemotherapy in breast cancer. Breast Cancer Res Treat, 108, 183-90. DOI ScienceOn |